The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1638
Booster Doses of COVID-19 Vaccines
Download PDF:   US English
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
Additional Contributor(s)
  • Michael Viscusi, Pharm.D., Associate Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the recommendations for use of COVID-19 vaccine booster doses based on level of risk and previous vaccination history.
 Select a term to see related articles     Comirnaty   COVID-19   Spikevax   vaccines 
Revised 11/29/21: This article originally went to press on 11/10/21. On 11/19/21 the FDA changed their recommendations. We have included a revision note to reflect these changes.

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.

RECOMMENDATIONS — A single booster dose of any COVID-19 vaccine can now be administered ≥6 months after a primary series of an mRNA-based vaccine in adults who are ≥65 years old or at high risk for severe COVID-19 because of an underlying medical condition or frequent institutional or occupational exposure to SARS-CoV-2, or ≥2 months after a single primary dose of the Johnson & Johnson vaccine in any adult (see Table 1).1,2 Revised: As of November 19, 2021, the FDA has expanded the EUAs for the mRNAbased COVID-19 vaccines (Comirnaty and Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one.19

DOSAGE — The booster dose is the same as the dose for primary immunization for both Comirnaty (30 mcg [0.3 mL] IM) and the Johnson & Johnson vaccine (5x1010 viral particles [0.5 mL] IM); it is half the dose for primary immunization for Spikevax (50 mcg [0.25 mL] vs 100 mcg [0.5 mL] IM).3-5

CLINICAL STUDIES — Waning Immunity – In a retrospective cohort study of ~3.4 million persons ≥12 years old in the US, those who received two doses of Comirnaty were significantly less likely to be infected with SARS-CoV-2 than those who were not vaccinated, but the relative risk reduction associated with vaccination declined from 88% at ≤1 month to 47% at ≥5 months after the second dose. Vaccination was also associated with a lower risk of hospitalization due to COVID-19; the relative risk reduction did not change significantly over time (87% at ≤1 month; 88% at ≥5 months).6

In a study in Israel that examined positive PCR test results for SARS-CoV-2 infection over 3 weeks in July 2021, adults ≥60 years old who completed a 2-dose primary series of the Pfizer/BioNTech vaccine in the second half of January 2021 had a significantly higher rate of infection than those who completed their series in the second half of March 2021 (3.3 vs 1.7 cases/1000 persons). Similarly, adults ≥60 years old who completed their series in January had a significantly higher rate of severe COVID-19 than those who completed it in March (0.34 vs 0.15 cases/1000 persons).7

In a US study of breakthrough infection rates between July 1 and August 27, 2021 in ~26,000 adults who had received primary immunization with Spikevax, the rate in an earlier-vaccinated (median 13 months since first dose) cohort was 36.4% higher than that in a later-vaccinated (median 8 months since first dose) cohort (77.1 vs 49.0 cases/1000 person-years).8

The efficacy of the Johnson & Johnson vaccine appears to be sustained through at least 6 months post-dose, but the peak efficacy of a single Johnson & Johnson dose seems to be lower than that of a 2-dose primary series of an mRNA-based vaccine.9-11

Booster Immunogenicity – Longitudinal immunogenicity studies (unpublished; summarized in FDA Fact Sheets) compared titer levels of anti-SARS-CoV- 2 neutralizing antibodies after a booster dose to those achieved after completion of primary immunization in adults with no evidence of prior SARS-CoV-2 infection. In 210 adults 18-55 years old who received a booster dose of Comirnaty about 6 months after completion of a 2-dose primary series, the geometric mean titer (GMT) 1 month after the booster dose was 3.29-fold higher than it was 1 month after the second primary-series dose.3 In 149 adults who received a 50-mcg booster dose of Spikevax ≥6 months after completion of a 2-dose primary series, the GMT 4 weeks after a 50-mcg booster dose was 1.8-fold higher than it was 4 weeks after the second primary-series dose.5 In 38 adults who received a booster dose of the Johnson & Johnson vaccine 12 weeks after a primary dose, the GMT 4 weeks after the booster dose was 1.6-fold higher than it was 4 weeks after the primary dose.4

Booster Efficacy – In a one-month cohort study in ~1.1 million Israeli residents who had completed a 2-dose primary series of the Pfizer/BioNTech vaccine ≥5 months previously, persons who received a booster dose had significantly lower rates of SARS-CoV-2 infection (by 11.3-fold) and severe COVID-19 (by 19.5-fold) beginning 12 days after administration compared to those who did not.12 In a follow-up analysis, relative reductions in the rates of symptomatic and severe COVID-19 associated with booster immunization persisted through ~2 months after the booster dose, and among persons ≥60 years old, the rate of death due to COVID-19 was 14.7-fold lower beginning 12 days after administration in patients who received a booster dose than it was in those who did not receive one.13

In an unpublished double-blind trial (ENSEMBLE 2; summarized in an FDA presentation), 31,300 persons were randomized to receive two doses of the Johnson & Johnson vaccine or placebo 8 weeks apart. After a median follow-up of 36 days, the vaccine efficacy rate for prevention of moderate to severe COVID-19 from 14 days after the second dose, the primary endpoint, was 75% (94% in the US). There were no cases of severe or critical COVID-19 in vaccine recipients versus 8 in the placebo group. This data analysis was performed in June 2021, before the Delta variant of SARS-CoV-2 became predominant in the US.11

Heterologous ("Mix-and-Match") Boosters – In an unpublished nonrandomized trial (summarized in an FDA presentation), 458 adults who had received primary immunization with one of the three FDA-authorized COVID-19 vaccines ≥12 weeks previously were given a booster dose of either the same vaccine or one of the two other vaccines (for Spikevax, 100-mcg rather than 50-mcg booster doses were used). For all vaccine combinations, the GMT of anti-SARS-CoV-2 neutralizing antibodies increased significantly in the 2 weeks after the booster dose.14

ADVERSE EFFECTS — Adverse effects with a third dose of an mRNA-based COVID-19 vaccine appear to be similar to those with the second primary-series dose.15 Lymphadenopathy occurs more frequently with a booster dose. Booster immunization with mRNA-based COVID-19 vaccines has not been associated with increased rates of hypersensitivity reactions, Bell's palsy, or myocarditis/pericarditis compared to primary immunization.16,17

Adverse effects with a booster dose of the Johnson & Johnson vaccine appear to be similar to those with the primary dose. Booster immunization has not been associated with a higher rate of thrombosis with thrombocytopenia syndrome (TTS) compared to primary immunization with the vaccine. In the UK, the rate of TTS with the second dose of the adenovirus-based COVID-19 vaccine manufactured by AstraZeneca (not authorized for use in the US) has been lower than the rate with the first dose.11,18

No vaccine-related serious adverse effects were reported in the heterologous booster trial. Adverse effects with heterologous and homologous booster immunization appear to be similar.14

CONCLUSION — Booster immunization has been associated with decreased rates of SARS-CoV-2 infection and severe COVID-19. The FDA has authorized use of a single booster dose of a COVID-19 vaccine in certain adults who received a primary series with the Pfizer-BioNTech vaccine (Comirnaty) or the Moderna vaccine (Spikevax) ≥6 months previously and in all adults who received a primary dose of the Johnson & Johnson/Janssen vaccine ≥2 months previously. The vaccine used for the booster dose can be different from the one used for primary immunization.

Additional Content Available: COVID-19 Vaccine Dosing Recommendations

REFERENCES

  1. FDA News Release. Coronavirus (COVID-19) update: FDA takes additional actions on the use of a booster dose for COVID-19 vaccines. October 20, 2021. Available at: https://bit.ly/3vJJPLy. Accessed October 29, 2021.
  2. CDC News Release. CDC expands eligibility for COVID-19 booster shots. October 21, 2021. Available at: https://bit.ly/3CpoXft. Accessed October 29, 2021.
  3. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). October 20, 2021. Available at: https://bit.ly/37fX1NG. Accessed October 29, 2021.
  4. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). October 20, 2021. Available at: https://bit.ly/3e6KEaD. Accessed October 29, 2021.
  5. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). October 20, 2021. Available at: https://bit.ly/3nosylA. Accessed October 29, 2021.
  6. SY Tartof et al. Six-month effectiveness of BNT162b2 mRNA COVID-19 vaccine in a large US integrated health system: a retrospective cohort study. 2021 August 23 (preprint). Available at: https://bit.ly/3CJwzJ8. Accessed October 29, 2021.
  7. Y Goldberg et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med 2021 October 27 (epub).
  8. LR Baden et al. Covid-19 in the phase 3 trial of mRNA-1273 during the Delta-variant surge. medRxiv 2021 September 22 (preprint). Available at: https://bit.ly/3Gk9q2N. Accessed October 29, 2021.
  9. J Sadoff et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384:2187.
  10. JM Polinski et al. Effectiveness of the single-dose Ad26.COV2.S COVID vaccine. medRxiv 2021 September 16 (preprint). Available at: https://bit.ly/3EdYPVk. Accessed October 29, 2021.
  11. R Zhang and T Brennan. FDA review of effectiveness and safety of Janssen COVID-19 vaccine (Ad26.COV2.S) booster dose. Emergency Use Authorization amendment. Vaccines and Related Biological Products Advisory Committee Meeting. October 14-15, 2021. Available at: https://bit.ly/3k6a9eD. Accessed October 29, 2021.
  12. YM Bar-On et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021; 385:1393.
  13. YM Bar-On et al. Protection across age groups of BNT162b2 vaccine booster against Covid-19. medRxiv 2021 October 7 (preprint). Available at: https://bit.ly/3jy9h1Q. Accessed October 29, 2021.
  14. KE Lyke. DMID 21-0012 – heterologous platform boost study: mix and match. Vaccines and Related Biological Products Advisory Committee Meeting. October 14-15, 2021. Available at: https://bit.ly/2Zk5NcB. Accessed October 29, 2021.
  15. AM Hause et al. Safety monitoring of an additional dose of COVID-19 Vaccine — United States, August 12–September 19, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1379.
  16. J Lee. FDA review of effectiveness and safety of COMIRNATY (COVID-19 vaccine, mRNA) booster dose. Biologics License Application supplement. Vaccines and Related Biological Products Advisory Committee Meeting. September 17, 2021. Available at: https://bit. ly/2ZhqsgQ. Accessed October 29, 2021.
  17. T Mongeau. FDA review of effectiveness and safety of Moderna COVID-19 vaccine (mRNA-1273) booster dose. Emergency Use Authorization amendment. Vaccines and Related Biological Products Advisory Committee Meeting. October 14, 2021. Available at: https://bit.ly/3Be97mq. Accessed October 29, 2021.
  18. UK Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine – weekly summary of Yellow Card reporting. October 21, 2021. Available at: https://bit.ly/3pFVHO1. Accessed October 29, 2021.
  19. In Brief: Booster doses of mRNA-based COVID-19 vaccines for all adults. Med Lett Drugs Ther 2021; 63:202.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article